A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. 1994

S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
Rauha Hospital, Finland.

Fifty-seven inpatients with major depression (DSM-III-R) entered a 12-week study comparing paroxetine and imipramine. Trends (not reaching statistical significance) in favour of paroxetine were seen on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Rating Scale (MADRS). The UKU Side Effect Rating Scale showed a significant difference in favour of paroxetine on reduced salivation. Global evaluation of side effect symptoms showed that significantly more paroxetine patients had no side effects, both in the investigators' and the patients' opinion. These results are in line with previous findings of paroxetine being an effective and well tolerated antidepressant.

UI MeSH Term Description Entries
D007099 Imipramine The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. Imidobenzyle,Imizin,4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2),Imipramine Hydrochloride,Imipramine Monohydrochloride,Imipramine Pamoate,Janimine,Melipramine,Norchlorimipramine,Pryleugan,Tofranil
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006760 Hospitalization The confinement of a patient in a hospital. Hospitalizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
January 1993, International clinical psychopharmacology,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
February 1992, The Journal of clinical psychiatry,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
June 1992, International clinical psychopharmacology,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
December 1973, Current therapeutic research, clinical and experimental,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
June 1993, Journal of affective disorders,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
April 1989, Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
December 1992, The Journal of clinical psychiatry,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
January 1989, Acta psychiatrica Scandinavica. Supplementum,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
May 1997, Pharmacopsychiatry,
S L Arminen, and U Ikonen, and P Pulkkinen, and E Leinonen, and A Mahlanen, and H Koponen, and K Kourula, and J Ryyppö, and V Korpela, and M L Lehtonen
June 1992, International clinical psychopharmacology,
Copied contents to your clipboard!